203 completed, 33 recruiting, 24 withdrawn, 21 terminated. 310 Phase 2, 35 Phase 1, 35 Phase 3.
Follow Narcotic-Related Disorders: new trials by email Literature Review of Narcotic-Related Disorders trials Research Report on Narcotic-Related Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dynamic Treatment Regimes for Opioid Use Disorder Medication for opioid use disorder, psychotherapy - Opioid Use Disorder | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 75 | 2028-07-01 | 2025-11-04 |
| Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo - Opioid Use Disorder, Opioid Withdrawal | Phase 1 / Phase 2 | Not yet recruiting | Clive Michelsen | 60 | 2027-07-01 | 2026-10-13 |
| Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder Psilocybin - Opioid Use Disorder | Phase 2 | Withdrawn | Johns Hopkins University | 2027-04-01 | 2026-02-23 | |
| Naloxone for Opioid Associated Out of Hospital Cardiac Arrest Naloxone 2 MG, Saline 2ml - Heart Arrest, Out-Of-Hospital, Opioid Overdose | Phase 2 | Not yet recruiting | University of California, San Francisco | 98 | 2027-03-01 | 2026-09-11 |
| Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons naltrexone implant - Opioid Use Disorder | Phase 2 | Not yet recruiting | Go Medical Industries Pty Ltd | 250 | 2027-01-01 | 2026-09-28 |
| A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain Cebranopadol, Placebo - Chronic Pain, Pain | Phase 2 | Recruiting | Adneuris Therapeutics, Inc. | 45 | 2026-10-01 | 2026-10-23 |
| Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder Yohimbine + Hydrocortisone, Active rTMS, Placebo - Opioid Use Disorder | Phase 2 | Not yet recruiting | Wayne State University | 20 | 2026-10-01 | 2025-12-30 |
| Ketones for Opioid Craving Treatment with Ketone Supplement, Treatment with Placebo - Opioid Use Disorder | Phase 2 | Recruiting | University of Maryland, Baltimore | 50 | 2026-07-16 | 2026-08-25 |
| Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual Buprenorphine SL, Telehealth, In-person treatment as usual - Opioid Use Disorder | Phase 2 | Withdrawn | New York State Psychiatric Institute | 2026-06-01 | 2026-09-08 | |
| Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder Sustained-release Dexamphetamine, Placebo - Cocaine Use Disorder | Phase 2 | Recruiting | Parnassia Addiction Research Centre | 204 | 2026-04-22 | 2026-05-29 |
| A Study of Brenipatide in Participants With Opioid Use Disorder Brenipatide, Placebo, Buprenorphine - Opioid Use Disorder | Phase 2 | Recruiting | Eli Lilly and Company | 465 | 2026-02-13 | 2026-10-07 |
| Ketamine for Opioid Use Disorder Treatment with Ketamine, Treatment with Very Low Dose Ketamine - Opioid Use Disorder | Phase 2 | Recruiting | University of Maryland, Baltimore | 50 | 2026-02-04 | 2026-10-20 |
| Serious Game to Teach Opioid Overdose Response Serious game training - Opioid Overdose | Phase 2 | Not yet recruiting | University of Nevada, Reno | 850 | 2026-02-01 | 2024-12-11 |
| Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement Ketamine, Mindfulness-Oriented Recovery Enhancement (MORE), Support Group - Opioid Use Disorder | Phase 2 | Not yet recruiting | University of California, San Diego | 88 | 2026-02-01 | 2026-02-03 |
| Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder Tirzepatide, Placebo - Opioid Use Disorder, Opioid Use Disorder, Moderate | Phase 2 | Recruiting | T. John Winhusen, PhD | 310 | 2026-01-29 | 2026-08-11 |
| PATH to Reducing Burnout Among Peers Who Deliver Overdose Prevention Services (R61 Phase Pilot) PATH (Peer Advanced Training for total Health) - Burnout, Compassion Satisfaction | Phase 2 | Completed | Chestnut Health Systems | 18 | 2026-01-12 | 2026-10-16 |
| Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage Lidocaine, Lidocaine and Dexamethasone - Subarachnoid Hemorrhage, Aneurysmal, Headache | Phase 2 | Recruiting | The University of Texas Medical Branch, Galveston | 15 | 2026-01-02 | 2026-01-09 |
| Psilocybin on Brain Mechanisms of Motivation in OUD Psilocybin (high dose), psilocybin (low dose) - Opioid Use Disorder | Phase 2 | Recruiting | University of Pennsylvania | 24 | 2025-12-22 | 2026-07-09 |
| Psilocybin for Opioid Use Disorder (OUD) Psilocybin - Opioid Use Disorder | Phase 2 | Recruiting | NYU Langone Health | 480 | 2025-12-17 | 2026-01-23 |
| Extended-release Buprenorphine as a Novel Low-dose Induction Strategy Extended-release Buprenorphine - Opioid Use Disorder | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 8 | 2025-10-27 | 2026-07-09 |
Showing 20 of 310. Sign in to see all of them.
Opioid-Related Disorders (276) · Substance-Related Disorders (45) · Heroin Dependence (26) · Opioid-Induced Constipation (24) · Chronic Pain (18) · Cocaine-Related Disorders (15) · Constipation (14) · Behavior, Addictive (13) · Pain (11) · Acquired Immunodeficiency Syndrome (6) · Agnosia (6) · HIV Infections (6) · Lymphoma, Follicular (4) · Alcoholism (3)
Chemically-Induced Disorders (308) · Mental Disorders (308) · Substance-Related Disorders (265) · Pathological Conditions, Signs and Symptoms (59) · Signs and Symptoms (55) · Neurologic Manifestations (31) · Signs and Symptoms, Digestive (25) · Behavior (24) · Immune System Diseases (15) · Nervous System Diseases (14) · Pain (14) · Compulsive Behavior (13) · Impulsive Behavior (13) · Urogenital Diseases (13)
Buprenorphine (70) · Buprenorphine, Naloxone Drug Combination (28) · Naltrexone (21) · vivitrol (12) · Methadone (10) · Naloxone (9) · Oxycodone (9) · lofexidine (8) · Cannabidiol (7) · Morphine (7) · Psilocybin (7) · Tramadol (7) · Hydromorphone (6) · Therapeutics (6) · Ketamine (5)
National Institute on Drug Abuse (NIDA) (39) · New York State Psychiatric Institute (30) · Yale University (26) · Johns Hopkins University (21) · University of Pennsylvania (10) · University of Vermont (8) · Indivior Inc. (7) · University of Chicago (7) · University of Colorado, Denver (7) · Brigham and Women's Hospital (6) · University of Maryland, Baltimore (6) · University of California, Los Angeles (5) · Wayne State University (5) · Glycyx Therapeutics (4) · Acura Pharmaceuticals Inc. (3)
United States (267) · Canada (7) · Russia (4) · United Kingdom (4) · China (3) · France (3) · Denmark (2) · Germany (2) · Malaysia (2) · Norway (2) · Spain (2) · Switzerland (2) · Albania (1) · Armenia (1) · Austria (1)
Warren Bickel, Ph.D. (17) · Walter Ling, M.D. (9) · James Zacny, Ph.D. (7) · Leslie Amass, Ph.D. (6) · Sandra D Comer, PhD (6) · Marc I Rosen, M.D. (5) · Adam Bisaga, MD (4) · Charles O'Brien, M.D., Ph.D. (4) · Eric C. Strain, MD (4) · Thomas R Kosten, M.D. (4) · Kenneth Silverman, Ph.D. (3) · Richard S. Schottenfeld, M.D. (3) · Richard Schottenfeld, M.D. (3)
PMID 40342086, PMID 20707781, PMID 21782353, PMID 25175864, PMID 37584841, PMID 11058673, PMID 12873949, PMID 1517644, PMID 15734224, PMID 15919269, PMID 16002025, PMID 16102908, PMID 16870915, PMID 17341537, PMID 17581533, PMID 17933486, PMID 18586174, PMID 19283561, PMID 20079977, PMID 20513828, PMID 20589494, PMID 20631574, PMID 21320227, PMID 21467190, PMID 21489407, PMID 21513688, PMID 21715107, PMID 21998076, PMID 22013534, PMID 22079773, PMID 22227789, PMID 22233189, PMID 22281120, PMID 23049275, PMID 23159524, PMID 23335901, PMID 23337942, PMID 23572466, PMID 23874575, PMID 23952897, PMID 24153411, PMID 24227768, PMID 24674234, PMID 25563446, PMID 25602580, PMID 25784600, PMID 25823919, PMID 25866297, PMID 25912739, PMID 25975386
R01DA008391 (7), R01DA006969 (6), R01DA011160 (6), K20DA000191 (5), P50DA009236 (3), R01DA005626 (3), R01DA018125 (3), R01DA019497 (3), R01DA008045 (2), R01DA009803 (2), R01DA010746 (2), R01DA014718 (2), 1UG3DA050325-01 (1), 1UG3DA062088-01 (1), 2009 (1)